DCM
VOR icon

DGS Capital Management’s Vor Biopharma VOR Stock Holding History

DGS Capital Management’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,765
Closed -$89.6K – 459
2025
Q2 		$89.6K Hold
2,765
– – 0.02% 347
2025
Q1 		$39.7K Buy
+2,765
New +$66.4K 0.01% 315

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Ariose Capital Management Central, Hong Kong, Hong Kong $234M AUM 640.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DGS Capital Management's VOR Position: Q3 2025 in Review

DGS Capital Management sold out of Vor Biopharma (VOR) in Q3 2025, closing a stake of 2,765 shares — an estimated $89.6K sold.

DGS Capital Management first reported a position in VOR in Q1 2025 and held it in 2 quarters. The position peaked at $89.6K in Q2 2025. 37 funds tracked by Wall St. Rank hold VOR as of Q3 2025.

  • DGS Capital Management reported no remaining Vor Biopharma position as of Q3 2025 after selling out during the quarter.
  • DGS Capital Management sold 2,765 Vor Biopharma shares in Q3 2025, an estimated $89.6K.
  • DGS Capital Management first reported a position in Vor Biopharma in Q1 2025 and held it in 2 quarters.
  • DGS Capital Management's Vor Biopharma position peaked at $89.6K in Q2 2025.
  • 37 funds tracked by Wall St. Rank held Vor Biopharma as of Q3 2025.

Based on DGS Capital Management's 13F filing for Q3 2025, filed 24 Feb 2026.